Abivax SA soared about 1,300% after successful trial results for a bowel disease drug, Argenx SE was added to the elite Euro ...
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on ...
French biotech company Abivax's shares rose by over 20% on Wednesday on market rumours that U.S. pharma giant Eli Lilly could ...
Abivax Presents Third Quarter 2025 Financial Results Cash and cash equivalents of EUR 589.7 (as of September 30, 2025) with a cash runway into Q4 ...
TipRanks on MSN
Abivax price target raised to $131 from $114 at Citizens
Citizens raised the firm’s price target on Abivax (ABVX) to $131 from $114 and keeps an Outperform rating on the shares. Abivax reported Q3 ...
Abivax stock skyrocketed in July after the company announced overwhelmingly positive topline results from its Phase 3 ...
Abivax receives a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ...
This article first appeared on GuruFocus. Abivax SA (XPAR:ABVX) is set to release its Q3 2025 earnings on Dec 15, 2025. The ...
DelveInsight's Ulcerative Colitis Market Insights report includes a comprehensive understanding of current treatment practices, ulcerative colitis emerging drugs, market share of individual therapies, ...
Abivax CEO Marc de Garidel discusses the future growth of the company, after this year's meteoric rally. Massive data breach ...
French biotech company Abivax SA started the year with a market value of less than $500 million. After a meteoric rally, it’s now worth more than $8 billion — and some analysts see the potential for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results